Biocon bolsters pharma subsidiaries with fresh preference share funding

Biocon Limited ( (IN:BIOCON) ) just unveiled an update.

Biocon has injected fresh capital into its wholly owned subsidiaries Biocon Biosphere and Biocon Pharma by acquiring large tranches of optionally convertible redeemable non-cumulative preference shares in each entity. The funding is aimed at meeting working capital, capex and general corporate needs, reinforcing the operational and financial support structure within the group while maintaining arm’s-length terms despite the related-party status.

The move signals Biocon’s intent to strengthen its pharmaceutical subsidiaries’ balance sheets and sustain growth in their respective businesses, with Biocon Pharma already a significantly larger revenue contributor than Biocon Biosphere. By channeling funds through preference shares, the parent retains flexibility on future conversion while ensuring that key units have sufficient resources to pursue ongoing projects and expansion plans.

More about Biocon Limited

Biocon Limited is an India-based biopharmaceutical company operating in the pharmaceuticals sector, with a focus on developing and manufacturing complex generics, biosimilars and specialty products for global markets. Through subsidiaries such as Biocon Biosphere Limited and Biocon Pharma Limited, it addresses both active pharmaceutical ingredients and finished dosage formulations, serving diverse therapeutic areas.

Average Trading Volume: 145,426

Technical Sentiment Signal: Strong Buy

Current Market Cap: 628.9B INR

For an in-depth examination of BIOCON stock, go to TipRanks’ Overview page.